C4 Therapeutics (CCCC) Stock
Clinical stage biotech developing therapies to remove disease proteins. Here's the price, business snapshot, and what's worth knowing about C4 Therapeutics in October 2026.
C4 Therapeutics, Inc (CCCC) is a clinical‑stage biotechnology company focused on targeted protein degradation — small molecules designed to harness the cell’s protein disposal machinery to remove disease‑causing proteins. With a market capitalisation of roughly $228.5m, C4 is a small‑cap, research‑driven enterprise whose outlook hinges on clinical trial results, regulatory milestones and potential partnerships. Investors get exposure to an innovative therapeutic approach that could address previously “undruggable” targets, but that potential comes with high uncertainty: long development timelines, binary clinical outcomes, and ongoing funding needs that can dilute shareholders. Key considerations include the company’s pipeline progress, cash runway, collaborator agreements and the competitive landscape for degraders. This summary provides general educational information only and is not personalised investment advice; returns are not guaranteed and the value of shares can fall as well as rise.
C4 Therapeutics (CCCC) Stock Forecast
Analyst price target, next 12 months
$15.25
+416.9% vs today's $2.95
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering C4 Therapeutics have a consensus 12-month target of $15.25, above the current price of $2.95.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 Aug 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying C4 Therapeutics' stock with a target price of $15.25, indicating strong potential growth.
Financial Health
C4 Therapeutics is showing moderate revenue and cash flow, indicating stable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical milestones ahead
Upcoming trial readouts can move the stock substantially; positive data may unlock partnerships, though outcomes are binary and uncertain.
Novel therapeutic approach
Targeted protein degradation offers access to previously hard‑to‑drug targets, but scientific and regulatory hurdles remain.
Financing and runway
As a small‑cap biotech, C4 will likely need capital over time; that can enable development but may also dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
